title: Assessing onset of treatment benefit in depression and anxiety: conceptual considerations.
abstract: OBJECTIVE
  Methods for characterizing the onset of treatment benefit in major depressive disorder and generalized anxiety disorder have been studied for some time, yet there is no universal agreement as to the best approaches. Our purpose is to summarize the conceptual framework underlying modern methods for characterizing onset and detailed approaches for which there is consensus from the perspective of a clinician, clinical researcher, and statistician. Possible alternatives to unresolved issues are discussed.
  
  
  METHODS
  There were 17 experts from academia, the pharmaceutical industry, and the US Food and Drug Administration who met on April 19, 2007, to consider the issues. Many others from sponsoring firms observed the proceedings.
  
  
  METHODS
  A series of papers was presented at a consensus meeting and, after discussions, a sense of the participants was obtained. A small group subsequently reviewed the material and articles from the literature and prepared this article, which was reviewed by all of the participants.
  
  
  CONCLUSIONS
  The elements that form the basis for describing onset of treatment benefit include defining a clinical event or measurable threshold that validly signals that a treatment has begun to provide clinically meaningful and sustained improvement and utilizing methods for estimating the probability of crossing the onset threshold, the distribution of time to onset for those who do cross, and when to alter or change interventions if the treatment is unsuccessful.
authors.affiliation: New York University School of Medicine, New York, NY, USA. laska@nki.rfmh.org
authors.forename: Eugene M
authors.initials: EM
authors.lastname: Laska
authors.forename: Craig H
authors.initials: CH
authors.lastname: Mallinckrodt
authors.forename: Jim C
authors.initials: JC
authors.lastname: Mundt
authors.forename: Paul
authors.initials: P
authors.lastname: Leber
authors.forename: Anthony L
authors.initials: AL
authors.lastname: Vaccarino
authors.forename: Amir H
authors.initials: AH
authors.lastname: Kalali
authors.forename: John H
authors.initials: JH
authors.lastname: Greist
mesh_terms: D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D003245:Consensus Statements as Topic; D003865:Major Depressive Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D010919:Placebos; D011569:Psychiatric Status Rating Scales / Q000706:statistics & numerical data; D011594:Psychometrics; D016032:Randomized Controlled Trials as Topic; D012720:Severity of Illness Index; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D010919:Placebos